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Genital herpes is one of the most prevalent sexually transmitted infections in both the 
developing and developed world. Following infection, individuals experience life-long 
latency associated with sporadic ulcerative outbreaks. Despite many efforts, no vaccine 
has yet been licensed for human use. Herein, we demonstrated that nasal immunization 
with an adjuvanted HSV-2 gD envelope protein mounts significant protection to primary 
infection as well as the establishment of latency and recurrent genital herpes in guinea 
pigs. Nasal immunization was shown to elicit specific T cell proliferative and IFN-γ 
responses as well as systemic and vaginal gD-specific IgG antibody (Ab) responses. 
Furthermore, systemic IgG Abs displayed potent HSV-2 neutralizing properties and high 
avidity. By employing a competitive surface plasmon resonance (SPR) analysis combined 
with a battery of known gD-specific neutralizing monoclonal Abs (MAbs), we showed 
that nasal immunization generated IgG Abs directed to two major discontinuous neutral-
izing epitopes of gD. These results highlight the potential of nasal immunization with an 
adjuvanted HSV-2 envelope protein for induction of protective immunity to primary and 
recurrent genital herpes.
Keywords: genital herpes, nasal immunization, neutralizing antibody, competitive surface plasmon resonance 
assay, sexually transmitted infection, vaccine
inTrODUcTiOn
HSV-2 is the leading cause of genital herpes, one of the most prevalent sexually transmitted infections 
(1). HSV-2 enters via the epithelium of the genital tract mucosa, where it replicates, and transfers 
to the sensory neurons innervating the infected area. The virus establishes life-long latency in the 
dorsal root ganglia (DRG), where it can sporadically reactivate and cause recurrent genital herpes 
disease (2). Re-infection of epithelial cells during recurrent outbreaks may lead to symptomatic or 
asymptomatic HSV-2 shedding (3). During the silent latent phase of HSV infection the latency-
associated transcript (LAT) is the only RNA transcribed and is therefore used as a latency marker (4).
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To date, no vaccine against genital herpes is available for human 
use. A few subunit vaccine candidates using systemic immuniza-
tion have reached advanced clinical trials with disappointing 
results (5–7). Earlier studies by our group and others have dem-
onstrated that nasal immunization with adjuvanted recombinant 
HSV-2 glycoproteins can confer protective immunity to primary 
genital herpes infection in mice (8–12). However, little is known 
about the potential of mucosal immunization for induction of 
protective immunity to primary HSV-2 infection, establishment 
of latency and recurrent genital outbreaks in guinea pigs, which is 
the most clinically relevant animal model of the disease [reviewed 
in Ref. (13)]. Likewise, while the importance of antibodies (Abs) 
in protective immunity to primary genital herpes has been exten-
sively studied in mice (14–19), the neutralizing characteristics of 
the Ab response elicited after mucosal immunization remains 
poorly understood. In the present study, we attempted to investi-
gate these important issues in a guinea pig model of the disease. 
We opted to use gD protein as a prototype HSV-2 antigen owing 
to its essential role in mediating the binding of the virus to two 
major cellular receptors (herpesvirus entry mediator (HVEM) 
and nectin-1) and activating the downstream components of 
the viral fusion machinery i.e., gH/gL and gB (20). Furthermore, 
gD possesses the ability to induce virus-neutralizing Abs, and as 
such its antigenic structure has been well studied using a large 
panel of anti-gD monoclonal Abs (MAbs) (21, 22). We employed 
a biosensor-based MAb-blocking assay along with HSV-2 neu-
tralization assay to decipher whether nasal immunization with 
adjuvanted gD protein could elicit high avidity IgG Ab responses 
against epitopes overlapping those of well-characterized MAbs 
and whether this IgG Ab response has neutralizing properties.
We report herein that nasal immunization with CpG-
adjuvanted gD protein evokes high avidity neutralizing IgG Abs 
against two discontinuous gD epitopes overlapping those of 
well-characterized MAbs. Furthermore, we showed that nasal 
immunization confers protective immunity to primary genital 
herpes, establishment of latency, and recurrent outbreaks in 
guinea pigs. These results provide new insights into the potential 
of nasal immunization to elicit protective immunity to genital 
herpes.
MaTerials anD MeThODs
animals
Female Dunkin-Hartley guinea pigs (350–450 g) and C57BL/6 
mice (7–9  weeks old) were purchased from Charles River, 
Germany. Female μMT mice (8–10  weeks old) on C57BL/6 
background were bred in-house (kindly provided by MIVAC, 
University of Gothenburg, Sweden). The animals were housed 
under specific-pathogen-free conditions at the Experimental 
Biomedicine Animal Facility, University of Gothenburg. When 
required, the animals were sedated with Isofluran (Baxter 
Healthcare). The guinea pigs were euthanized with an intraperi-
toneal overdose of pentobarbital, followed by heart removal. The 
mice were sacrificed by cervical dislocation. All experiments were 
conducted with the approval (311-12) of the Ethical Committee 
for Animal Experimentation in Gothenburg, Sweden.
Virus
HSV-2 strain 333 was grown and titrated in African green 
monkey kidney cells [GMK-AH1; (23)], according to a previous 
publication (10).
immunization scheme
Groups of guinea pigs (in total n  =  15–18) were nasally 
immunized three times, at 14-day intervals, with 50  µg 
recombinant HSV-2 gD (24) alone or together with 150  µg 
CpG ODN 7909 (TCG TCG TTT TGT CGT TTT GTC GTT) 
(Eurofins MWG/Operon), in 250 µl. Groups of mice (in total 
n = 5) were nasally immunized three times, at 7-day intervals, 
with 5 µg gD together with 15 µg CpG ODN 1826 (TCC ATG 
ACG TTC CTG ACG TT) (Eurofins MWG/Operon), in 20 µl. 
Phosphate buffered solution (PBS) was used for dilutions 
and a group given PBS was included as negative control in all 
experiments. The inoculum was divided equally between the 
nostrils with a micropipette in sedated animals. Three studies 
were performed for guinea pigs and two studies for the mice. 
Results shown are pooled from the experiments unless stated 
otherwise.
Proliferative analysis in guinea Pigs
Four weeks past, the final immunization blood samples were 
withdrawn from the heart, into a syringe containing heparin 
(500 U), of guinea pigs under deep sedation. After euthanasia, 
spleen and para-aortic/iliac lymph nodes (herein referred to as 
genital lymph nodes (gLN)) were excised. Lymphoid organs were 
mashed against filter papers and cells pelleted by centrifugation 
at 400 × g (Thermo Multifuge 3S-R), 5 min, 4°C. Erythrocytes 
in splenocyte suspensions were lysed with ammonium chloride 
(5 ml/spleen) at 37°C. PBMCs were isolated from blood by using 
Histopaque 1083 (Sigma-Aldrich). All cells were suspended in 
Iscove’s medium, containing 10% fetal bovine serum, 100 µg/ml 
gentamicin sulfate, 50 µM 2-β mercaptoethanol, all from Sigma-
Aldrich, in addition to 2 mM l-glutamine (Biochrom). Cells were 
seeded in sterile 96-well plates (Nunc), 2 ×  105 per well, with 
gD (2  µg/ml) or Concanavalin A (2.5  µg/ml) (Sigma-Aldrich), 
as positive control, and incubated at 37°C, 5% CO2. Selected 
plates were used to collect cells at 24 and 48 h. The remaining 
cells were incubated with 1 μCi of [6-3H] thymidine (Amersham 
Biosciences) for 6–8  h, at 72  h, before frozen at −20°C. The 
cell proliferation was analyzed by a scintillation counter (1450 
MicroBeta Trilux) as counts per minute.
Serum samples from guinea pigs. Blood samples were retrieved, 
by puncturing hind leg v. saphena, 4 weeks after the final immuni-
zation. Samples were left to coagulate at room temperature (RT), 
centrifuged twice at 600 × g for 5 min at 4°C (Thermo Sci., Fresco 
17), and the sera were frozen at −20°C.
Vaginal swab samples from guinea Pigs
The vaginal vault, of sedated guinea pigs, was swabbed with a 
100 mm swab (MicroRheologics) dipped in PBS 4 weeks post-
immunization. The brush part was then placed in 300 µl PBS on 
ice. Supernatants were recovered from vortexed and centrifuged 
(600 × g, 5 min, 4°C) samples and stored at −20°C.
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analysis of gD-specific ab levels
The content of gD-specific Abs were determined in serum 
and vaginal swab samples by ELISA, as previously described 
(10). Horseradish peroxidase-conjugated goat α-guinea pig 
IgA (Immunology Consultants Laboratory) or IgG (Southern 
Biotech) antibodies were used for detection.
serum igg Purification
Pearl IgG spin columns (GBiosciences) were used to purify 
IgG Abs from guinea pig sera according to the manufacturer’s 
protocol. Briefly, 200 µl resin was added to a column, after which 
10-fold diluted serum samples were added in a 500 µl-volume. 
After purification, samples were adjusted to 0.2  mg/ml based 
on Nanodrop spectrophotometer (Thermo Scientific) protein 
concentration. Purified samples were stored at −20°C.
avidity Measurements of igg with elisa
Avidity of gD-specific IgG Abs in sera was measured using the 
aforementioned ELISA protocol, with the addition of a potassium 
thiocyanate (KSCN) elution step (25). Briefly, 100  µl of serum 
samples, diluted 50-fold in PBS-Tween 20 with BSA (1%), were 
added to gD-coated plates and incubated for 2 h at 37°C. After 
washing with PBS-Tween 20, twofold dilutions of KSCN, rang-
ing from 0.125 M to 8 M, or PBS-Tween 20 (representing 100% 
binding) were added and incubated for 15 min at RT. The reaction 
was developed and absorbance read at 450 nm. The results were 
expressed as an avidity index, defined as the M KSCN needed to 
dissociate 50% of bound IgG Abs.
avidity Measurements with surface 
Plasmon resonance (sPr)
Anti-His Abs (His capture kit, GE) were immobilized onto a CM5 
sensor chip (~13,800 response unit (RU)), and His-tagged gD was 
flowed over to immobilize gD at approximately 1,200 RU using 
a Biacore 4000 SPR instrument (GE Healthcare, Biacore Life 
Sciences). Purified IgG samples flowed over the chip to observe 
the binding and dissociation phases. A control flow cell was 
immobilized with an equimolar amount of BSA, and all data were 
normalized to sensograms from this control flow cell. All samples 
were run in two independent experiments with reversed sample 
order, each consisting of one anti-His flow cell and one control 
(BSA) flow cell. Relative avidity was determined by taking the 
average maximal binding during the association phase divided 
by the dissociation rate constant (kD) to yield the avidity score 
(RU × s). The results from the two independent experiments were 
averaged.
gD-specific competitive sPr
Competitive SPR experiments were performed using the dual 
channel SPR SR7500DC System (Reichert Technologies Life 
Sciences, Buffalo, NY, USA) with a NiCH 1000 M sensor chip 
(XanTec bioanalytics GmbH, Düsseldorf, Germany) at RT. 
Filtered and degassed HBS-EP buffer (10 mM HEPES, pH 7.4, 
150 mM NaCl, 3 mM EDTA, 0.005% Tween 20) was used as run-
ning buffer. The sensor chip was activated by a 3 min-injection 
of nickel sulfate solution (40 mM), followed by injection of ethyl 
dimethylaminopropyl carbodiimide (40 mg/ml) together with N 
hydroxysuccinimide (10 mg/ml) to the left channel. gD protein 
(50 µg/ml) was injected to the left channel for 5 min and 1,300 
RU was immobilized onto the sensor chip. For surface deac-
tivation, ethanaolamine (1 M, pH 8.5) was injected for 8 min 
into the left channel, followed by injection of EDTA (350 mM) 
for 3  min to rinse non-covalently bound protein. The com-
petitive SPR experiment was performed as explained elsewhere 
(26). Briefly, purified guinea pig serum IgG Abs (100  µg/ml) 
were injected for 180 s to both the left and the right channel, 
after which gD-specific mouse MAbs 1D3, DL11, MC2, MC5, 
MC14, MC23 (22, 27, 28) (75–150 µg/ml) were injected to both 
channels for 180 s. The right channel was used as a reference, 
to record background binding. After each round, the surface of 
the sensor chip was regenerated by injection of NaOH (50 mM) 
for 1 min until the RU signal returned to the baseline. All injec-
tions were performed at a flow rate of 25 µl/min. The blocking 
activity of each guinea pig IgG sample was calculated for each 
MAb as a percentage using the following formula: [1 −  (RU 
MAb binding to human IgG-coated chip/RU MAb binding to 
control chip)] × 100.
hsV-2 neutralization assay
Serum samples, serially diluted in Iscove’s complete medium, 
were pre-incubated with 300  plaque-forming units (PFU) of 
HSV-2 strain 333 for 2  h, 37°C, 5% CO2. The pre-incubated 
virus was applied to GMK-AH1 cells, grown 2 × 104 cells/well 
in sterile 96-well plates (Nunc). The cell plates were left at RT for 
1 h, followed by 3 days of incubation at 37°C, 5% CO2. Cells were 
stained with Crystal violet (Sigma-Aldrich), and the cytopathic 
effect was examined by microscopy in a blinded fashion. HSV-2 
neutralization was considered as the highest possible dilution of 
sera at which a 50% reduction of plaques was observed relative 
to the virus control.
Vaginal hsV-2 challenge
HSV-2 challenge of guinea pigs was conducted 4  weeks post-
immunization. The vaginal vault was pre-swabbed with HBSS 
and 2 × 105 PFU of HSV-2 strain 333 was administered with a 
micropipette under anesthesia. Three weeks after the final immu-
nization, mice were injected subcutaneously with 3 mg of Depo-
Provera (Pzifer), diluted in PBS, in order to increase susceptibility 
to infection by inducing diestrus. Six days later, the mice were 
anesthetized and challenged intravaginally with 9 × 104 PFU of 
HSV-2 strain 333.
Vaginal sampling
Vaginal fluids were collected from guinea pigs and mice 3 days 
post-infection for viral plaque assay. In one of the guinea pig 
experiments samples were retrieved twice a week during the 
latent phase of infection (13  days in total) in order to study 
viral shedding. The vaginal vault of guinea pigs were swabbed 
and washed with 300  µl Hank’s balanced salt solution. After 
centrifugation, 200 × g, 5 min, 4°C, supernatants were retrieved 
in order to avoid excess mucus. Two 40 µl-washes were collected 
from mice in a total volume of 1 ml HBSS. Samples were stored 
at −80°C until use.
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hsV-2 Plaque assay
Vaginal HSV-2 levels post-infection were determined by plaque 
assay as previously described (10). Guinea pig samples were 
tested in 10- and 50-fold dilutions, while mouse samples were 
tested in a 10-fold dilution. Virus levels were recorded as PFU/ml 
vaginal sample.
inflammation and Disease
Guinea pigs were monitored daily for 65 days after HSV-2 chal-
lenge. The severity of disease was graded as: 0 = healthy, 1 = swell-
ing and/or genital erythema, 2 = a few small vesicles, 3 = several 
confluent ulcerated vesicles, 4  =  ulcerated lesions, purulent 
inflammation, incontinence, and 5 = large disseminated lesions, 
severe weight loss, neurological symptoms. Recurrent symptoms 
were considered as newly emerged genital vesicles (score 2 and 
above) arising after day 14 post-challenge. Mice were examined 
daily for up to 14  days post-challenge. The severity of disease 
was graded as: 0 = healthy, 1 = genital erythema, 2 = moderate 
genital inflammation, 3 =  severe genital lesions, and 4 =  hind 
limb paralysis. Guinea pigs and mice were sacrificed as soon as 
they displayed signs of severe illness (scores 5 and 4, respectively).
isolation of nervous Tissues
Guinea pigs surviving the HSV-2 infection were sacrificed 
between day 65 and 70 post-infection and the lumbosacral 
DRG were collected. Pooled DRG from naive guinea pigs were 
used as control in the real-time PCR experiments. Spinal cord 
and lumbosacral DRG were collected from all sacrificed mice, 
irrespective of day.
Quantification of iFn-γ mrna and hsV-2 
mrna/Dna by real-Time Pcr
Guinea pig gLN cells (24 h), splenocytes and PBMCs (48 h) col-
lected after in vitro gD recall stimulation, were washed twice in PBS, 
pelleted and frozen at −80°C. Guinea pig DRG and mouse DRG/
spinal cord were collected in RNAlater and subsequently stored 
at −80°C. All reagents for RNA preservation, RNA/DNA extrac-
tions as well as cDNA synthesis (Qiagen GmbH Germany) were 
used following the manufacturer’s recommendations. Total RNA 
was extracted with RNeasy mini kit, co-purification of RNA/DNA 
was performed with Allprep DNA/RNA mini kit and DNA from 
vaginal swab samples was purified by DNeasy blood and tissue 
kit. All RNA/DNA preparations that passed quality tests were 
used for downstream analysis. The concentration and absorb-
ance ratios of RNA/DNA were determined with a Nanodrop 
spectrophotometer. The QuantiTect Reverse Transcription kit 
was used for cDNA preparation, including a DNA wipeout step. 
Real-time PCR on the cDNA (50 ng/reaction) and DNA (100 ng/
reaction) samples was carried out in duplicate. MicroAmp 
Optical plates and Power SYBR Green PCR Master Mix were used 
for detection and plates were run in an ABI 7500 real-time PCR 
system, all three from Applied Biosystems, UK. Primers guinea 
pig IFN-γ mRNA were forward, 5′- AGGAGACGATTTGGCT 
CTGA-3′, and reverse, 5′-GAAGTTCTTTGGACCTGATCG-3′ 
(29). Primers HSV-2 LAT mRNA were forward, 
5′-GTCAACACGGACACACTCTTTTT-3′, and reverse, 
5′-CGAGGCCTGTTGGTCTTTATC-3′ (30). The size of the 
PCR product for each primer set was verified on ethidium bromide 
agarose gel. The amplification efficiency of the PCR reactions was 
verified by analyzing samples in serial dilution. The specificity 
of primers targeting LAT was confirmed by submitting the PCR 
product (from two positive samples) for sequencing, after which 
a Blast search was performed. Housekeeping gene hypoxan-
thine phosphoribosyl transferase was used for normalization, 
using primers forward, 5′-AGGTGTTTATCCCTCATGGAC 
TAATT-3′, and reverse, 5′-CCTCCCATCTCCTTCATCAC 
AT-3′. Data were analyzed by the ΔCt method. Fold changes of 
IFN-γ in gD-stimulated cells were calculated against unstimulated 
cells from the same individual. Fold changes of IFN-γ in DRG 
were calculated against data from naïve guinea pigs. Fold changes 
>4 were considered positive. Quantification of HSV-2 DNA 
was performed by gB gene amplification with primers forward, 
5′-TGCAGTTTACGTATAACCACATACAGC-3′, and reverse 
5′-AGCTTGCGGGCCTCGTT-3′ (31). HSV-2 DNA (Advanced 
Biotechnologies) was used for calculation of the number of viral 
genome copies. The standard curve was based upon eight differ-
ent concentrations, which ranged from 104 down to 10 genome 
copies per reaction. The mean R2 value for the standard curves 
was 0.985. The detection threshold was 8 genome copies/reaction.
statistical analysis
GraphPad Prism 6 (GraphPad Software) was used for statisti-
cal analysis. Data from three groups were analyzed by one-way 
ANOVA followed by the Tukey multiple comparison test (CI 
95%). Data sets involving two groups were analyzed with a two-
tailed unpaired t test (95% CI). Survival data were evaluated with 
the Kaplan–Meier method and the Log-rank test. Correlation was 
computed by non-parametric Spearman test. Differences were 
considered statistically significant at p values of <0.05 (*), <0.01 
(**), and <0.001 (***).
resUlTs
nasal immunization Provides significant 
Protection to Primary genital herpes 
infection in guinea Pigs
First, we investigated the potential of nasal immunization for 
induction of protection against primary genital herpes in a guinea 
pig model of the disease. Guinea pigs were immunized three 
times with gD singly or in combination with CpG ODN 7909 
or were left unimmunized. Four weeks after the final immuniza-
tion the animals were inoculated vaginally with 2 × 105 PFU of 
HSV-2. Following challenge, all unimmunized (17/17) and the 
majority (12/15) of the gD immunized guinea pigs showed signs 
of erythema, blisters, and ulcers around the opening of their vagi-
nal vaults and in few animals neurological symptoms emerged 
(Figure 1A). However, the majority of the gD group survived the 
infection (12/15), while over half of the controls (10/17) showed 
severe symptoms requiring euthanizia (Table 1). Among those 
that recovered from the primary infection, the recovery was faster 
in the gD immunized animals compared with the unimmunized 
group (Figure 1A). In sharp contrast, the guinea pigs immunized 
Table 1 | Disease progression in hsV-2 guinea pig model.
immunizationa Primary infection latent infection
skin 
diseaseb
replicationc survivald skin 
diseaseb
sheddinge
Control 15/17 16/17 7/17 7/7 3/13
gD 12/15 11/15 12/15 10/12 7/65
gD + CpG 7/18 5/18 18/18 12/18 7/104
aGuinea pigs immunized according to Figure 1.
bIndividuals displaying minimum score 2 (one or more vesicles)/total individuals 
challenged.
cPositive vaginal swabs for HSV-2 replication by plaque assay/total samples tested.
dSurvivors/total individuals challenged.
eDays tested positive for vaginal HSV-2 gB DNA/total days tested (single experiment).
FigUre 1 | nasal immunization in guinea pigs mounts protective immunity to primary genital herpes, establishment of viral latency and recurrent 
outbreaks. Groups of female guinea pigs were immunized nasally with gD alone or together with CpG three times with 14 days interval. A control group given the 
diluent PBS was also included. Four weeks following the last immunization guinea pigs (n = 15–18) were challenged vaginally with 2 × 105 plaque forming units 
(PFU) of HSV-2, thereafter monitored daily for symptoms of disease. The guinea pigs surviving primary infection (n = 7–18) were continued to be monitored daily for 
up to day 65 post-challenge for symptoms of recurrent outbreaks. At day 65–70 post-infection, ganglia were isolated from the animals and RNA was purified alone 
or co-purified with DNA from the ganglia, and the levels of mRNA and DNA were determined by real-time PCR. (a) Disease progression during primary HSV-2 
infection (day 0–14 post-challenge). Disease symptoms scored as 0 = healthy, 1 = swelling and/or genital erythema, 2 = a few small vesicles, 3 = several confluent 
ulcerated vesicles, 4 = ulcerated lesions, purulent inflammation, incontinence, and 5 = large disseminated lesions, severe weight loss, neurological symptoms. 
Guinea pigs were euthanized as soon as displaying severe signs of illness (score 5). (b) The level of vaginal HSV-2 titers on day 3 post-challenge displayed as PFU/
ml. (c) Disease progression during latent HSV-2 infection (day 15–65 post-challenge) shown as mean cumulative disease score over time (n = 7–18). (D) RNA 
extracted from ganglia (n = 6–17) was quantified by real-time PCR with primers specific for HSV-2 LAT. The results are shown as 2−δCT of LAT. (e) Viral DNA copies in 
ganglia shown as the number of HSV-2 genome copies per 100 ng DNA (n = 5–12). (F) IFN-γ transcript in dorsal root ganglia (DRG) (n = 6–17) expressed as fold 
change over the mean expression in naïve guinea pigs. The dotted line in (D–F) displays the detection threshold. Results in (a,b) are expressed as the 
mean ± SEM. The end points in (a,c) as well as the data in (b) and (D–F) were analyzed by one-way ANOVA followed by Tukey multiple comparison test (CI 95%), 
with differences statistically significant at p values of <0.05 (*), <0.01 (**), and <0.001 (***).
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with gD + CpG displayed no or mild symptoms (7/18) of the dis-
ease and all animals survived the primary infection (Figure 1A; 
Table  1). Furthermore, this group showed virtually no detect-
able virus titers in their genital secretions (Figure 1B, p < 0.001 
compared with the control group). In summary, nasal-mucosal 
immunization with gD + CpG confers strong protective immu-
nity against an otherwise severe primary genital HSV-2 infection 
in guinea pigs (Table 1).
nasal immunization engenders Protection 
against establishment of latency and 
recurrent genital hsV-2 in guinea Pigs
After recovery from the primary genital HSV-2 infection, the 
guinea pigs continued to be monitored daily for 65  days after 
challenge. In most animals, the first recurrence episode started 
after day 25 post-challenge (Figure 1C). All controls surviving the 
primary HSV-2 infection displayed recurrent disease (7/7), with 
a high episode rate and long-lasting outbreaks (mean recurrent 
days = 21). In the gD immunized group, the recurrent outbreak 
was observed in 83% of the survivors, with a relatively high fre-
quency and long-lasting symptoms (mean recurrent days = 13, 
ns compared with the control group). Although several of the 
gD +  CpG group showed mild signs of recurrent disease, the 
symptoms emerged at a later stage were of significantly shorter 
6Persson et al. Nasal Immunization and HSV-2 Neutralizing Antibodies
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duration and less frequent compared with those of the control 
and the gD immunized guinea pigs (mean recurrent days = 5, 
p < 0.001 compared with the control group) (Figure 1C; Table 1). 
Importantly, one third of the gD + CpG immunized guinea pigs 
remained free of symptoms of recurrent genital HSV-2 infection 
throughout the experiment (Table 1).
Next, we investigated the establishment of latency in the 
lumbosacral DRG on day 65–70 after challenge in all guinea pigs 
surviving the primary infection. All but one guinea pig from the 
control group tested positive for ganglionic LAT mRNA (positive: 
5/6, 2−δCt LAT: 0.555 ± 0.214), as did the majority of the gD group 
(positive: 9/12 positive, 2−δCt LAT: 0.368 ± 0.113) (Figure 1D). In 
line with the protection data, LAT expression was virtually unde-
tectable in the gD + CpG immunized guinea pigs. Nevertheless, 
LAT was detectable, albeit at very low levels, in the DRG of the 
gD + CpG guinea pigs that exhibited recurrent disease (positive: 
12/17, 2−δCt LAT: 0.032 ± 0.010).
Next, we quantified HSV-2 DNA copies in the DRG samples 
by gB-specific PCR. The majority of the DRG samples from the 
control and the gD group contained HSV-2 DNA (positive: 4/5 
control and 6/11 gD), while most gD + CpG immunized guinea 
pigs tested negative (positive: 2/12) (Figure 1E). The expression 
of LAT was found to correlate strongly with viral DNA copy 
number in the ganglia (rS = 0.81) (Figures 1D,E; Table 1).
In addition, we assessed IFN-γ mRNA level in DRG as a sur-
rogate marker for latent infection as reported previously (32, 33). 
Several of the challenged guinea pigs displayed IFN-γ expression 
in their DRG with a pattern similar to that of HSV-2 LAT mRNA 
(positive: 4/6 control, 10/12 gD, and 9/16 gD + CpG) (Figure 1F).
Taken together, these results demonstrate that nasal immuni-
zation with gD in combination with CpG induced considerable 
protection against establishment of latency and recurrent genital 
herpes in guinea pigs.
antigen-specific T cell and ab responses 
induced Following nasal immunization in 
guinea Pigs
Four weeks after the final immunization, splenocytes, PBMCs, 
and gLN cells were isolated and tested for proliferative responses 
and IFN-γ mRNA levels after antigen recall stimulation in vitro. 
The gD immunized guinea pigs did not show any appreciable 
increase in antigen-specific proliferation and IFN-γ responses 
over the PBS control group (Figures 2A,B). The gD + CpG group, 
on the other hand, displayed an antigen-specific proliferative 
response and IFN-γ expression by their splenocytes, PBMCs and 
gLN cells (Figures 2A,B).
While the vaginal secretions of the guinea pigs immunized 
with gD alone contained a modest serum gD-specific IgG Ab 
response, the guinea pigs given gD +  CpG demonstrated sig-
nificantly higher antigen-specific serum IgG Ab titers in their 
vaginal secretion samples (p  <  0.001 compared with the gD 
group) (Figures 2C,D). No systemic or vaginal gD-specific IgA 
Abs could be detected in any of the groups (data not shown). 
Taken together, these data show that nasal immunization could 
mount systemic antigen-specific T cell responses as well as strong 
mucosal and systemic IgG Ab responses in guinea pigs.
Functional analysis of the ab response 
induced Following nasal immunization in 
guinea Pigs
Next, we sought to explore the quality and function of the Ab 
response induced after nasal immunization in guinea pigs. First, 
we assessed the avidity of the gD-specific IgG Abs by ELISA 
and SPR assay. The gD + CpG immunized guinea pigs showed 
significantly higher avidity of gD-specific IgG Abs compared to 
those of the gD immunized animals, both by ELISA and SPR 
(p < 0.001) (Figure 2E). To further analyze the function of the 
vaccine-induced Abs, we analyzed their HSV-2 neutralizing 
properties. As expected, sera collected from the control group 
showed no neutralization, and the level was also low for the gD 
immunized animals (Figure  2E). On the contrary, sera from 
the gD + CpG group showed significantly more potent HSV-2 
neutralization compared with that of the gD group (p < 0.001) 
(Figure  2F). The HSV-2 neutralization effect was shown to be 
independent of the complement system, as heat-inactivation 
did not affect the neutralizing properties of the sera (data not 
shown). There was a significant inverse correlation between 
serum neutralization capacity and the severity of the primary 
disease (rS = −0.71, p < 0.001, Figure 2G), vaginal HSV-2 titers 
post-infection (rS = −0.75, p < 0.001, Figure 2H) and number of 
days with recurrence (rS = −0.59, p < 0.001, Figure 2I).
It has recently been shown that HSV-2 neutralization activity 
of sera collected from humans vaccinated with a gD subunit vac-
cine correlated with the presence of IgG Abs that target epitopes 
overlapping those of the gD-specific MAbs DL11, MC2, MC5, 
and MC23 (26). As sera derived from the guinea pigs immunized 
with gD +  CpG exhibited a high HSV-2 neutralizing capacity, 
we examined if the Abs raised in guinea pigs after nasal immu-
nization could target any of these known HSV-2 neutralizing 
epitopes. To address this, we tested the binding of purified guinea 
pig IgG Abs to the antigen in a competitive SPR assay by using 
six well-characterized gD-specific MAbs: 1D3, DL11, MC2, MC5, 
MC14, and MC23, all shown to exert HSV neutralizing properties 
singly or in combination with other MAbs (22, 27, 28). The MAbs 
1D3, DL11, MC5, and MC14 bound efficiently to the gD protein 
immobilized on the sensor chip and thus included in the blocking 
SPR experiments. MC2 and MC23 MAb failed to bind efficiently 
to the gD protein on the sensor chip and were therefore omitted 
from further analysis (data not shown).
All purified IgG samples efficiently blocked the binding of 
the HSV-2 neutralizing MAbs DL11 and MC5 to the gD protein 
(51–94%). In addition, two of the guinea pig IgG Ab samples 
partially hindered the association of 1D3 to gD (22–31%), while 
none blocked the binding of MC14 more than 20% (Figure 3). 
These results indicate that nasal immunization with gD + CpG 
elicits a gD-specific IgG Ab response with high neutralizing 
capacity, targeting the two known neutralizing discontinuous 
epitopes recognized by DL11 and MC5 MAbs (Figure 3).
nasal immunization Fails to elicit 
Protective immunity in ab Deficient Mice
Next, we evaluated the importance of gD-specific Ab responses 
induced by nasal immunization in protective immunity to genital 
FigUre 2 | characterization of immune responses elicited after nasal immunization in guinea pigs. Guinea pigs were immunized as explained in Figure 1. 
Four weeks after the final immunization cells isolated from spleen, blood, and genital lymph nodes (gLN) were re-stimulated with gD protein in vitro. (a) After 72 h, 
splenocytes, PBMC and gLN cells (n = 4) were harvested and proliferation recorded as counts per minutes. (b) The RNA samples obtained from the cultured cells 
at 24 (gLN) and 48 h (spleen and PBMC) were analyzed for IFN-γ mRNA levels by real-time PCR. Results show IFN-γ expression in gD-stimulated cells expressed 
as fold change over unstimulated cells. (c,D) The content of gD-specific IgG in sera and vaginal swabs taken 4 weeks after the last immunization was determined 
by a gD-specific ELISA (n = 15–18). Results are expressed as titer (Log10), based on the mean optical density (OD) value at 490 nm with a threshold of 0.4 above 
the background OD. (e) HSV-2 neutralization effect of sera was examined by a HSV-2 neutralization assay on monolayers of GMK-AH1 cells. The neutralizing 
properties of sera are presented as the highest dilution factor resulting in 50% reduction of the cytopathic effect. (F) Avidity of gD-specific IgG in sera measured by 
surface plasmon resonance (SPR) and KSCN based ELISA. SPR data presented as avidity score (response unit (RU)/dissociation rate constant (kD)[RU × s]) and 
ELISA data as avidity index. Serum neutralization capacity plotted against (g) primary disease score (top score), (h) vaginal HSV-2 replication at day 3 post-
challenge and (i) the number of recurrent days. The Spearman correlation coefficient is indicated in each plot. Data in (a,b) are expressed as the mean + SEM. 
Individual guinea pig data in (c–i) are represented by each dot and the lines in (c–F) indicate the mean value for each individual group. Results shown in (a,b) are 
pooled from two independent experiments. Results shown in (c,F,i) are pooled from three independent experiments. Data in (a–e) were analyzed by a one-way 
ANOVA followed by Tukey multiple comparison test (CI 95%), while the results in (F) were analyzed with a two-tailed unpaired t test and 95% CI. Differences were 
considered statistically significant at p values of <0.05 (*), <0.01 (**), and <0.001 (***).
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herpes using mice lacking mature B cells (μMT mice). Groups of 
female age-matched C57BL/6 and μMT mice were immunized 
nasally with gD in combination with CpG ODN 1826 three times 
or were left unimmunized. Four weeks after the last immuniza-
tion, mice were treated with progesterone followed by a vaginal 
challenge with a lethal dose of HSV-2. The gD + CpG immunized 
wild-type mice showed no symptoms of the disease (Figure 4A), 
100% survival (Figure 4B) and no or very low viral loads in their 
vaginal secretions (Figure 4C).
Further, viral DNA was absent or very low in the spinal cord 
(Figure 4D) and the DRG (Figure 4E) of these mice compared 
with those of the control wild-type mice, indicating a neuro-
protective effect of the immunization. In contrast, the nasally 
immunized μMT mice lacking mature B cells and Ab succumbed 
FigUre 3 | igg antibodies (abs) raised after nasal immunization in guinea pigs targets epitopes overlapping those of known neutralizing gD 
monoclonal abs (Mabs). IgG purified from sera of guinea pigs immunized nasally with gD + CpG were subjected to a biosensor surface plasmon resonance 
blocking assay using the gD-specific MAbs DL11, MC5, 1D3, and MC14. The binding between the individual MAbs and the gD protein immobilized onto the sensor 
chip was recorded by a biosensor, and the results are expressed as response unit (RU). A gD-coated sensor chip was then first exposed to purified guinea pig IgG 
after which the MAbs were injected sequentially after which the binding between the MAbs and gD was recorded. Data obtained from the association between the 
MAbs and the gD protein, in the absence of the blocking MAbs, are represented by black lines. Red lines show changes in RU of IgG samples with the ability to 
reduce the binding of the respective MAbs by more than 20%. Gray lines represent changes in RU of IgG samples with the ability to block the binding of the 
respective MAbs less than 20%. The percentage of reduction in the inhibition of the binding between the MAbs and the gD protein is shown for each IgG sample.
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FigUre 4 | The protective immunity conferred by nasal immunization is critically dependent on functional b cells. Female μMT and wild-type C57BL/6 
mice were immunized with gD together with CpG three times, with 1 week interval. Four weeks later, the immunized mice along with a PBS-treated control groups 
were given progesterone, followed 6 days later by a vaginal challenge with a lethal dose of HSV-2. (a) Disease progression after HSV-2 challenge (n = 5). Symptoms 
of the disease were scored as 0 = healthy, 1 = genital erythema, 2 = moderate genital inflammation, 3 = severe genital lesions, and 4 = hind limb paralysis for 
14 days after challenge. (b) Survival rate after the viral challenge over a period of 14 days (n = 5). (c) HSV-2 levels in the vagina at day 3 after challenge, displayed 
as plaque forming units per mL (n = 5). (D,e) Spinal cord and DRG were collected at the time of sacrifice and tested for the presence of HSV-2 DNA (n = 5). Results 
displayed as genome copies per 100 ng sample DNA. The numbers shown above the bars represent the number of positive samples. Data points in (c–e) 
represent individual mice and the lines indicate the mean value of each group. Statistical significance for the end points in (a) and between the groups in (c–e) was 
calculated with a two-tailed unpaired t test and 95% CI. Survival (b) was analyzed by the Kaplan–Meier method and the Log-rank test. Differences were considered 
statistically significant at p values of <0.05 (*), <0.01 (**), and <0.001 (***).
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to genital HSV-2 infection (Figures  4A–C). Accordingly, high 
levels of viral DNA copies were detected in the spinal cord and the 
ganglia of the μMT mice (Figures 4D,E). These results indicate 
that Abs play an important role for protection against genital 
HSV-2 infection induced by nasal immunization.
DiscUssiOn
We herein report that nasal immunization with CpG-adjuvanted 
HSV-2 gD protein confers protective immunity to primary geni-
tal herpes and recurrent outbreaks in guinea pigs. Furthermore, 
nasal immunization was shown to elicit high avidity, neutralizing 
IgG Abs directed against two discontinuous gD epitopes.
Earlier studies from our lab and others have documented the 
value of nasal immunization to mount protective immunity to 
primary genital herpes in mice (8–12). The potential of mucosal 
immunization with live attenuated/modified HSV-2 for preven-
tion of latency in the guinea pig model of the disease has previ-
ously been reported (34–38). Furthermore, nasal immunization 
with recombinant HSV-2 gD together with the adjuvant LTK63 
was shown to generate partial protection against primary genital 
herpes in guinea pigs (39). However, the impact of nasal immu-
nization on induction of protection against genital herpes latency 
and recurrence in the clinically relevant guinea pig model of the 
disease remains obscure.
We found that nasal immunization with gD +  CpG could 
induce significant protection to primary genital herpes infection 
as well as the establishment of latency and recurrent disease. The 
lumbosacral DRG of the immune guinea pigs, in sharp contrast to 
the controls, had no or very low levels of HSV-2 LAT. Ganglionic 
LAT transcript has been suggested to serve as the main surrogate 
of HSV reactivation and recurrent outbreaks (30, 33, 40). The 
level of LAT correlated with HSV-2 DNA found in the same DRG 
of the non-immune guinea pigs. This is in agreement with a study 
in which mutual presence of LAT and DNA was linked to the 
pattern of recurrent herpes (41).
We also showed that the establishment of latency and recur-
rences in guinea pigs is associated with the presence of IFN-γ 
mRNA in the DRG. This result is in line with previous reports 
indicating that IFN-γ production is associated with the establish-
ment of latency in the trigeminal ganglia (HSV-1) and lumbosa-
cral DRG (HSV-2) (32, 33, 42).
We documented that the nasal immunization of guinea 
pigs elicits systemic and vaginal specific IgG Ab responses. 
Furthermore, the sera from the nasally immunized guinea pigs 
had a potent HSV-2 neutralizing ability in vitro, and the neutral-
izing titers were found to correlate inversely with primary disease 
score, vaginal HSV-2 replication, and the number of recurrent 
days. The characteristics of a vaccine-induced Ab response 
remain poorly described in the HSV-2 guinea pig model. We 
demonstrated that the gD-specific serum IgG Abs raised follow-
ing nasal immunization possess high avidity and target epitopes 
overlapping those of the neutralizing MAbs DL11 and MC5. Both 
of these MAbs have the ability to block downstream activation 
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of the viral membrane fusion cascade. In addition, DL11 targets 
HSV binding to nectin-1 and HVEM and therefore neutralize 
HSV-2 efficiently (22, 43–47).
It has recently been shown in a recent large clinical trial of an 
exploratory vaccine composed of gD protein and AS04 adjuvant 
that neutralizing serum IgG Abs correlated with protection to 
genital HSV-1 infection (48). Importantly, the gD epitope profile 
of sera from our immunized guinea pigs matches that of vac-
cinated and naturally infected humans (26, 49), in that the sera 
of the immunized guinea pigs compete well with MAbs MC5 and 
DL11 but not with MAbs MC14 or 1D3. This is in contrast to sera 
from immunized rabbits, which contain Abs that readily block all 
four MAbs (unpublished data). The fact that humans and guinea 
pigs target the same gD epitopes lends further credence to the 
guinea pig model of genital HSV-2 infection.
None of the exploratory vaccines for genital herpes given 
by intramuscular injection has conferred protective immunity 
to genital HSV-2 in clinical settings [reviewed in Ref. (50)]. 
The mucosal route of immunization may thus be considered 
as an alternative route to mount protective immunity against 
genital herpes. Furthermore, the HSV gD protein has offered 
limited protection in human clinical trials. The value of inclu-
sion of additional key HSV proteins in vaccine to enhance the 
breadth of vaccine-induced immunity has been underpinned by 
encouraging results from multivalent therapuetic HSV-2 vaccine 
candidates tested in phase II clinical trials (51, 52).
In summary, results presented herein provide new insights 
into the potential of nasal immunization for induction of pro-
tection against primary and recurrent genital herpes as well as 
the characteristics of the induced Ab response in guinea pigs. 
These results may inform a rational development of vaccines 
against genital herpes and presumably other sexually transmitted 
infections.
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